New Reference: Obinutuzumab, ibrutinib, and venetoclax for Untreated CLL

Phase II, open label, multicenter (CLL-2-Give)

Previously untreated patients with high-risk chronic lymphocytic leukemia (CLL) with del(17p) and/or TP53 mutation

GIVe (Venetoclax + İbrutinib + Obinutuzumab) (n=41)

CR at cycle 15: 58.5% [42.1-73.7]

36 mos PFS: 79.9%

36 mos OS: 92.6%

Grade3 Aes: Neutropenia (48.8%), infections (19.5%), Atrial fibrillation (2.4%), hypertension (4.9%).

Reviewed by Elvin Chalabiyev, MD on Sep 23, 2023